Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brincidofovir for Ebola Virus Disease
NCT02271347Phase 2Withdrawn
- Sponsor
- Chimerix Inc.
- Start
- Oct 2014
- Primary completion
- Jan 2015
- Modality
- Metabolically Activated Prodrugs
01
Overview
Phase 2, open-label, single-arm trial of brincidofovir in Ebola virus disease (EVD), sponsored by Chimerix Inc. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 4 weeks. Planned start Oct 2014; status: withdrawn.
02
Drugs
brincidofovir
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02271347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271347.